Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

NEXT STORY
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
PREV STORY
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States

author_avatar
NASDAQ Market News

Helix BioPharma Corp. Closes $7.0 Million Private Placement

author_avatar
NASDAQ Market News

Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination

author_avatar
NASDAQ Market News